Protagenic Therapeutics, Inc. (PTIX)

NASDAQ: PTIX · IEX Real-Time Price · USD
1.350
-0.080 (-5.59%)
Apr 17, 2024, 2:04 PM EDT - Market open
-5.59%
Market Cap 5.12M
Revenue (ttm) n/a
Net Income (ttm) -5.00M
Shares Out 4.44M
EPS (ttm) -1.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 923
Open 1.340
Previous Close 1.430
Day's Range 1.153 - 1.350
52-Week Range 0.680 - 2.320
Beta 0.38
Analysts n/a
Price Target n/a
Earnings Date May 13, 2024

About PTIX

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 5, 2016
Employees 1
Stock Exchange NASDAQ
Ticker Symbol PTIX
Full Company Profile

Financial Performance

Financial Statements

News

Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit

Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical ...

6 hours ago - Accesswire

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Gen...

15 days ago - Accesswire

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mi...

21 days ago - Accesswire

Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call

Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Co...

22 days ago - Accesswire

Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice

NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid pric...

27 days ago - Accesswire

Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders

Company Anticipates Reporting Complete Phase I Single Dose Results in April NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, ...

2 months ago - Accesswire

Protagenic Therapeutics Announces Date of Annual Shareholder Meeting

NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, tod...

6 months ago - Accesswire

Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114

A potential major step toward treating stress-related neuro-psychiatric disorders NEW YORK, NY / ACCESSWIRE / September 26, 2023 / Today, Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneering biop...

7 months ago - Accesswire

Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split

Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESSWIRE / March 22, 2023 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX, the "Company") a biopharmaceuti...

1 year ago - Accesswire

Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th

NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic di...

2 years ago - Accesswire

Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today...

2 years ago - GlobeNewsWire

Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET

Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and A ddiction to be discussed

2 years ago - GlobeNewsWire

Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update

NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today...

2 years ago - GlobeNewsWire

Protagenic Therapeutics To Start Clinical Trials For Depression Candidate By 2021 End

Upon reviewing Protagenic Therapeutics Inc's (NASDAQ: PTIX) Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND. The application...

2 years ago - Benzinga

Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial

NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today...

2 years ago - GlobeNewsWire

Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today...

3 years ago - GlobeNewsWire

Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th

NEW YORK , June 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a bioharmaceutical company focused on developing drug product candidates to treat stress-related neurologic di...

3 years ago - GlobeNewsWire

Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq

New York, April 29, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the closing of an underwritten public offering of 3,180,000 units at a pu...

3 years ago - GlobeNewsWire

Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering

New York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a pu...

3 years ago - GlobeNewsWire